Development of novel therapies targeting at dysregulated signaling pathways in pulmonary arterial hypertension

doi:10.16352/j.issn.1001-6325.2024.08.1088

Abstract

Abstract: Pulmonary arterial hypertension (PAH) is a complex pulmonary vascular disease characterized by progressive elevation of mean pulmonary artery pressure resulted from the pathological feature of pulmonary vascular remodeling. Without medical intervention, PAH can eventually lead to right heart failure and death of patients. Up to the present, there are few treatment options for PAH are still mainly function through pulmonary vasodilation. Although these treatments can alleviate symptoms, the prognosis remains poor. In recent years, breakthroughs have been made in understanding the pathogenesis of PAH, thus support the development of new treatment strategies targeting at dysregulation of signaling pathways in PAH. This review focuses on five critical pathways and the relevant drugs those entered phase Ⅱ clinical trials and discusses their therapeutic potential, so to provide a basis for future research on targeting therapies for PAH patients.

Key words: pulmonary arterial hypertension, molecular pathways, ligands and receptors, targeted therapy, drug development

CLC Number:

R543.2

GAO Yidan, JIANG Xuehan, ZHANG Hong, YANG Peiran. Development of novel therapies targeting at dysregulated signaling pathways in pulmonary arterial hypertension[J]. Basic & Clinical Medicine, 2024, 44(8): 1088-1093.

References

[1] Mocumbi A, Humbert M, Saxena A, et al. Pulmonary hypertension[J].Nat Rev Dis Primers,2024,10:1.doi: 10.1038/s41572-023-00486-7.
[2] Humbert M,Kovacs G,Hoeper MM,et al.2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J].Eur Heart J,2022,43:3618-3731.
[3] Humbert M,Guignabert C,Bonnet S,et al.Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives[J]. Eur Respir J, 2019,53:1801887.doi: 10.1183/13993003.01887-2018.
[4] International PPH Consortium,Lane KB, Machado RD, et al.Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension[J].Nat Genet,2000,26:81-84.
[5] Evans JD, Girerd B, Montani D, et al.BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis[J].Lancet Respir Med,2016,4:129-137.
[6] Harrison RE, Flanagan JA, Sankelo M,et al.Molecular and functional analysis identifies ALK-1 as the predomi-nant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia[J].J Med Genet,2003,40:865-871.
[7] Reynolds AM, Holmes MD, Danilov SM, et al. Targeted gene delivery of BMPR2 attenuates pulmonary hyperten-sion[J]. Eur Respir J,2012,39:329-343.
[8] Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension[J]. N Engl J Med,2021,384:1204-1215.
[9] Hoeper MM,Badesch DB,Ghofrani HA,et al.Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension[J].N Engl J Med,2023,388:1478-1490.
[10] Zolty R. Pulmonary arterial hypertension specific therapy: the old and the new[J]. Pharmacol Ther, 2020,214:107576. doi: 10.1016/j.pharmthera.2020.107576.
[11] Sommer N, Ghofrani HA, Pak O,et al.Current and future treatments of pulmonary arterial hypertension[J]. Br J Pharmacol,2021,178:6-30.
[12] Gillies H, Niven R, Dake BT,et al. AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study[J]. ERJ Open Res, 2023,9:00433-2022. doi: 10.1183/23120541.00433-2022.
[13] Zolty R. Novel experimental therapies for treatment of pulmonary arterial hypertension[J].J Exp Pharmacol,2021,13:817-857.
[14] Ahmad R, Raina D, Meyer C,et al.Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179.[J]. J Biol Chem,2006,281:35764-35769.
[15] Liu A, Philip J, Vinnakota KC,et al. Estrogen maintains mitochondrial content and function in the right ventricle of rats with pulmonary hypertension[J].Physiol Rep, 2017, 5:e13157. doi: 10.14814/phy2.13157.
[16] Yang Y, Lin F, Xiao Z, et al.Investigational pharmacotherapy and immunotherapy of pulmonary arterial hypertension: an update[J]. Biomed Pharmacother, 2020,129:110355. doi: 10.1016/j.biopha.2020.110355.
[17] Kawut SM, Archer-Chicko CL, DeMichele A, et al. Anastrozole in pulmonary arterial hypertension. a randomized, double-blind, placebo-controlled trial[J]. Am J Respir Crit Care Med,2017,195:360-368.
[18] Grieco P, Gomez-Monterrey I. Natural and synthetic peptides in the cardiovascular diseases: an update on diagnostic and therapeutic potentials[J]. Arch Biochem Biophys, 2019,662:15-32.
[19] Hobbs AJ, Moyes AJ, Baliga RS, et al. Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial[J]. Br J Pharmacol, 2019,176:1251-1267.
[20] Leuchte HH, Baezner C, Baumgartner RA,et al.Inhalation of vasoactive intestinal peptide in pulmonary hypertension[J]. Eur Respir J, 2008, 32:1289-1294.